Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia

Dujovne, Carlos A.; Ettinger, Mark P.; McNeer, J F; Lipka, Leslie J.; LeBeaut, Alexandre; Suresh, Ramachandran; Yang, Bo; Veltri, Enrico P.

doi:10.1016/s0002-9149(02)02798-4

Cited by 354 publications

(240 citation statements)

References 10 publications

Supporting

Mentioning

212

Contrasting

Unclassified

Order By: Relevance

“…Ezetimibe has been shown in clinical studies of men and women to significantly reduce LDL-C but has minimal effects on HDL-C and triglycerides. 72,77 Safety data have been principally derived from short-term clinical studies, in which adverse effects and discontinuation rates were similar to those with placebo. 72,77 Ezetimibe has not been adequately evaluated in either pregnant or nursing women.…”

Section: Bile Acid Sequestrants/cholesterol Absorption Inhibitorsmentioning

confidence: 99%

Addressing Cardiovascular Disease in Women: Focus on Dyslipidemia

Meagher¹

2004

The Journal of the American Board of Family Medicine

View full text Add to dashboard Cite

Background: There is a need to better diagnose and treat women who may be at risk for cardiovascular disease. This is emphasized by the impending release of evidence-based guidelines for the prevention of cardiovascular disease in women. Dyslipidemia is one of the most important modifiable risk factors for coronary heart disease (CHD) and is the focus of the current literature review.Methods: Medical literature on treating cardiovascular disease and cholesterol disorders in women was reviewed by searching Medline, including a selective search for randomized controlled clinical trials of lipid therapy. In addition, current dyslipidemia treatment guidelines were reviewed.Results and

show abstract

Section: Bile Acid Sequestrants/cholesterol Absorption Inhibitorsmentioning

confidence: 99%

Addressing Cardiovascular Disease in Women: Focus on Dyslipidemia

Meagher¹

2004

The Journal of the American Board of Family Medicine

View full text Add to dashboard Cite

show abstract

“…Ezetimib'in risk faktörü durumu, milliyet, ırk, yaş veya başlangıç LDL-K düzeylerinden bağımsız olarak, LDL düşürücü etkisinin tüm alt gruplarda benzer olduğu sonucuna varılan çalışmaya da literatür-de rastlanmıştır (21) . Kolesterol emilim inhibitörleri olarak bilinen yeni lipit düşürücü ajan grubunun ilk örneği olan ezetimibin; primer hiperkolesterolemik olgulardaki etkinlik ve güvenilirliliğini değerlendiren araştırmalarda, ortalama LDL-K düzeyini % 18 azaltmış olduğunu gösterilmiştir (21,22) .…”

Section: Discussionunclassified

“…Kolesterol emilim inhibitörleri olarak bilinen yeni lipit düşürücü ajan grubunun ilk örneği olan ezetimibin; primer hiperkolesterolemik olgulardaki etkinlik ve güvenilirliliğini değerlendiren araştırmalarda, ortalama LDL-K düzeyini % 18 azaltmış olduğunu gösterilmiştir (21,22) .…”

Section: Discussionunclassified

The effect of ezetimibe monotherapy on lipoprotein-(a) and other lipid parameters

Bilir¹,

Takır²,

Sertbaş³

et al. 2015

MedJ

View full text Add to dashboard Cite

show abstract

“…However, the intestinal absorption of dietary and biliary cholesterol is also a major source of 4 cholesterol that affects lipid profiles [10]. Therefore, the inhibition of cholesterol absorption in the intestine is considered to be a potentially complementary component of lipid management.…”

Section: European and Other Societies On Cardiovascular Disease Prevementioning

confidence: 99%

Ezetimibe and Vascular Endothelial Function

Ikeda¹,

Maemura

2011

CVP

View full text Add to dashboard Cite

Hypercholesterolemia is a major risk factor for cardiovascular diseases that has been managed mostly with 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitors (statins) that suppress de novo cholesterol synthesis in the liver. Statins also have beneficial pleiotropic effects on the atherosclerotic process that are independent of their ability to lower lipid values. However, the levels of low-density lipoprotein cholesterol (LDL-C) in most hypercholesterolemic patients at high risk for cardiovascular disease do not reach the goals proposed by guidelines even when prescribed with statins. Ezetimibe is a new lipid-lowering agent that blocks the intestinal absorption of dietary and biliary cholesterol and reduces LDL-C levels, especially when combined with statins. However, its effect on cardiovascular events remains unknown. We reviewed the effects of ezetimibe on cardiovascular diseases, in particular, vascular endothelial function, which is initially impaired during the atherogenetic process and an important predictor of cardiovascular events. Increasing evidence suggests that ezetimibe improves endothelial function and nitric oxide availability, and reduces inflammation as well as oxidative stress. However, this mechanism has not been clarified and limited, large trials and cohort studies have not shown that this agent prevents cardiovascular events. Ezetimibe has just recently become commercially available, which might explain the paucity of evidence regarding its benefits and effects on cardiovascular morbidity and mortality.

show abstract

Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia

Cited by 354 publications

References 10 publications

Addressing Cardiovascular Disease in Women: Focus on Dyslipidemia

Addressing Cardiovascular Disease in Women: Focus on Dyslipidemia

The effect of ezetimibe monotherapy on lipoprotein-(a) and other lipid parameters

Ezetimibe and Vascular Endothelial Function

Contact Info

Product

Resources

About